title: Dynamic renal scintigraphy with 99mTc-DTPA for the assessment of renal function after therapy of acute lymphoblastic leukemia in children.
abstract: BACKGROUND
  Acute lymphoblastic leukemia (ALL) and its treatment may lead to impairment of kidney function. The aim of the present study was to evaluate kidney function in children after treatment of ALL. We used our 99mTc-DTPA (diethylene triamine pentaacetic acid labeled with 99mTc) dynamic scintigraphy protocol.
  
  
  METHODS
  The study group consisted of 48 ALL patients, aged 79-275 months, in complete remission (mean duration 51 months). Treatment was according to the guidelines of the Berlin Frankfurt Münster (BFM) BFM 86 and BFM 90 protocols in 36 (75%) and 12 (25%) children, respectively. Follow-up after treatment was up to 12 months in 10 (21%) children (group I), 12-60 months in 21 (44%) children (group II), and more than 60 months in 17 (35%) children (group III). 99mTc-DTPA dynamic renal scintigraphy was done in all patients. The glomerular filtration rate (GFR) was determined according to Gates and the diuretic test was done after 18 minutes of the examination.
  
  
  RESULTS
  The glomerular filtration rate at the end of the 5-year follow-up was less than 80 mL/min/1.73 m2 (p < 0.002) in 3 (25%) children treated with the BFM 86 protocol. In the remaining 45 (94%) patients, GFR exceeded 80 mL/ min/1.73 m2. Normal renogram curves were obtained in 40 (83%) patients. Eight (17%) children had cumulative curves with normal clearance. This finding was interpreted as non-obstructive uropathy. There was no statistical correlation between outflow disorders seen during dynamic scintigraphy, type of chemotherapy protocol, and assignment to risks group.
  
  
  CONCLUSIONS
  1. There was no clinically significant kidney function impairment in children after treatment of ALL. 2. Dynamic renal scintigraphy can be a valuable and non-invasive method for the assessment of kidney function in patients with a risk factor in the form of previous potentially nephrotoxic antitumor treatment.
authors.affiliation: Zakład Medycyny Nuklearnej Pomorskiego Uniwersytetu Medycznego w Szczecinie, ul. Unii Lubelskiej 1, 71-252 Szczecin.
authors.forename: Maria H
authors.initials: MH
authors.lastname: Listewnik
authors.forename: Jarosław
authors.initials: J
authors.lastname: Peregud-Pogorzelski
authors.forename: Bozena
authors.initials: B
authors.lastname: Birkenfeld
authors.forename: Monika
authors.initials: M
authors.lastname: Matacz
authors.forename: Piotr
authors.initials: P
authors.lastname: Zorga
authors.forename: Elwira
authors.initials: E
authors.lastname: Szychot
authors.forename: Hanna
authors.initials: H
authors.lastname: Piwowarska-Bilska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Brodkiewicz
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D002648:Child; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D007674:Kidney Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000628:therapy*; D011877:Radionuclide Imaging; D012074:Remission Induction; D016284:Technetium Tc 99m Pentetate; D055815:Young Adult
chemical_list: D016284:Technetium Tc 99m Pentetate